Catalyst Pharmaceuticals Inc Cash Flow Conversion Efficiency
Catalyst Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has a cash flow conversion efficiency ratio of 0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($59.59 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Catalyst Pharmaceuticals Inc (2004–2025)
Cash flow conversion efficiency of Catalyst Pharmaceuticals Inc from 2004 to 2025. This chart illustrates how Catalyst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CPRX share price today for real-time trading data and today's change.
Catalyst Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Catalyst Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Catalyst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see CPRX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hamilton Lane Inc
NASDAQ:HLNE
|
0.056x |
|
Linamar Corporation
TO:LNR
|
0.050x |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
0.051x |
|
Sonae SGPS SA
LS:SON
|
0.018x |
|
Do-Fluoride Chemicals Co Ltd
SHE:002407
|
0.026x |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
0.041x |
|
AMP Ltd
AU:AMP
|
-0.316x |
|
Haci Omer Sabanci Holding AS
IS:SAHOL
|
0.012x |
Annual Cash Flow Conversion Efficiency for Catalyst Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Catalyst Pharmaceuticals Inc from 2004 to 2025. Review Catalyst Pharmaceuticals Inc (CPRX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $954.27 Million | $208.67 Million | 0.219x | -33.65% |
| 2024-12-31 | $727.63 Million | $239.81 Million | 0.330x | -10.98% |
| 2023-12-31 | $387.88 Million | $143.60 Million | 0.370x | -4.16% |
| 2022-12-31 | $300.42 Million | $116.05 Million | 0.386x | +32.34% |
| 2021-12-31 | $206.83 Million | $60.37 Million | 0.292x | +9.92% |
| 2020-12-31 | $169.60 Million | $45.03 Million | 0.266x | -32.77% |
| 2019-12-31 | $87.63 Million | $34.61 Million | 0.395x | +178.03% |
| 2018-12-31 | $50.78 Million | $-25.70 Million | -0.506x | -198.20% |
| 2017-12-31 | $80.96 Million | $-13.74 Million | -0.170x | +62.86% |
| 2016-12-31 | $39.31 Million | $-17.96 Million | -0.457x | -40.72% |
| 2015-12-31 | $55.48 Million | $-18.02 Million | -0.325x | +11.57% |
| 2014-12-31 | $35.24 Million | $-12.94 Million | -0.367x | +20.46% |
| 2013-12-31 | $21.39 Million | $-9.88 Million | -0.462x | -31.32% |
| 2012-12-31 | $14.62 Million | $-5.14 Million | -0.352x | +73.48% |
| 2011-12-31 | $3.76 Million | $-4.99 Million | -1.326x | -94.66% |
| 2010-12-31 | $5.52 Million | $-3.76 Million | -0.681x | +32.48% |
| 2009-12-31 | $7.62 Million | $-7.68 Million | -1.009x | -28.94% |
| 2008-12-31 | $10.56 Million | $-8.26 Million | -0.782x | -188.55% |
| 2007-12-31 | $16.32 Million | $-4.42 Million | -0.271x | -356.52% |
| 2006-12-31 | $19.85 Million | $-1.18 Million | -0.059x | +94.18% |
| 2005-12-31 | $446.46K | $-455.36K | -1.020x | +47.98% |
| 2004-12-31 | $117.58K | $-230.52K | -1.961x | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more